Cross Country director's 29,759 shares cashed out
CROSS COUNTRY HEALTHCARE INC director Venkat Bhamidipati disposed of 29,759 shares of common stock on July 21, 2026 in connection with a merger.
Accepted by SEC EDGAR
Learn about SEC filing dates
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
CROSS COUNTRY HEALTHCARE INC director Venkat Bhamidipati disposed of 29,759 shares of common stock on July 21, 2026 in connection with a merger. The shares were converted into the right to receive $13.25 in cash per share under a merger agreement with KL Criss Cross Intermediate, LLC and its subsidiary, leaving him with no remaining shares of the issuer.
Insider Trade Summary
Disposition: 29,759 shares
Disposition
1 txn
Insider
Bhamidipati Venkat
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Common Stock F1, F2 | 29,759 | $13.25 | $394K |
Holdings After Transaction:
Common Stock — 0 shares (Direct)
Holdings Before and After:
Common Stock, 29,759 to 0 shares (Direct)
Footnotes (2)
- F1. Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 6, 2026, by and among Cross Country Healthcare, Inc., a Delaware corporation (the "Issuer"), KL Criss Cross Intermediate, LLC, a Delaware limited liability company ("Parent"), and KL Criss Cross Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Parent, (continued in footnote 2)
- F2. at the effective time of the Merger (the "Effective Time"), each (i) share of Issuer common stock ("Common Stock") issued and outstanding immediately prior to the Effective Time was automatically converted into the right to receive $13.25 in cash (the "Merger Consideration") and (ii) each restricted stock award with respect to shares of Common Stock outstanding immediately prior to the Effective Time was fully vested, cancelled and converted into the right to receive an amount in cash equal to the number of shares of Common Stock subject to such award immediately prior to the Effective Time multiplied by the Merger Consideration.
Key Figures
Shares disposed: 29759.0000 shares
Cash per share merger consideration: $13.25
Holdings after transaction: 0.0000 shares
+2 more
5 metrics
Shares disposed
29759.0000 shares
Common stock disposition to issuer on 2026-07-21
Cash per share merger consideration
$13.25
Amount in cash for each share of common stock at the Effective Time
Holdings after transaction
0.0000 shares
Common stock beneficially owned by the director following the merger-related disposition
Merger agreement date
May 6, 2026
Date of the Agreement and Plan of Merger among the issuer, Parent and Merger Sub
Restricted stock cash treatment
$13.25 per share
Each restricted stock award paid cash equal to underlying shares multiplied by $13.25
Key Terms
Agreement and Plan of Merger, Merger Consideration, Effective Time, wholly owned subsidiary
4 terms
Agreement and Plan of Merger regulatory
"Pursuant to the Agreement and Plan of Merger, dated as of May 6, 2026"
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger Consideration financial
"converted into the right to receive $13.25 in cash, the Merger Consideration"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
Effective Time regulatory
"at the effective time of the Merger, the Effective Time, each share of common stock"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
wholly owned subsidiary regulatory
"Issuer surviving the Merger as a wholly owned subsidiary of Parent"
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did CCRN report for director Venkat Bhamidipati?
Director Venkat Bhamidipati reported disposing of 29,759 shares of Cross Country Healthcare common stock. The July 21, 2026 transaction was a disposition to the issuer tied to a merger, rather than an open-market trade, with the shares converted into cash at $13.25 per share.
Did Venkat Bhamidipati’s CCRN transaction occur under a Rule 10b5-1 trading plan?
The transaction was not reported as occurring under a Rule 10b5-1 trading plan. The Form 4’s plan status indicator was unchecked, and the disposition instead arose automatically from the closing mechanics of the merger agreement, rather than from a pre-arranged trading program.
How were CCRN restricted stock awards treated in the Cross Country Healthcare merger?
Each restricted stock award outstanding immediately before the merger’s effective time was fully vested, cancelled and converted to cash. The cash payment equaled the number of underlying common shares in the award multiplied by the $13.25 merger consideration per share.
AI-generated analysis. How Rhea-AI works. Not financial advice.
